Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial.

Autor:	Edwards AL; Biogen, Cambridge, Massachusetts., Collins JA; Biogen, Cambridge, Massachusetts., Junge C; Ionis Pharmaceuticals, Carlsbad, California., Kordasiewicz H; Ionis Pharmaceuticals, Carlsbad, California., Mignon L; Ionis Pharmaceuticals, Carlsbad, California., Wu S; Biogen, Cambridge, Massachusetts., Li Y; Biogen, Cambridge, Massachusetts., Lin L; Biogen, Cambridge, Massachusetts., DuBois J; Biogen, Cambridge, Massachusetts., Hutchison RM; Biogen, Cambridge, Massachusetts., Ziogas N; Biogen, Cambridge, Massachusetts., Shulman M; Biogen, Cambridge, Massachusetts., Martarello L; Biogen, Cambridge, Massachusetts., Graham D; Biogen, Cambridge, Massachusetts., Lane R; Ionis Pharmaceuticals, Carlsbad, California., Budd Haeberlein S; Biogen, Cambridge, Massachusetts., Beaver J; Biogen, Cambridge, Massachusetts.
Jazyk:	angličtina
Zdroj:	JAMA neurology [JAMA Neurol] 2023 Dec 01; Vol. 80 (12), pp. 1344-1352.
DOI:	10.1001/jamaneurol.2023.3861
Abstrakt:	Importance: Accumulation of hyperphosphorylated, tangled microtubule-associated protein tau (MAPT) is a pathological hallmark of Alzheimer disease (AD) associated with disease progression and cognitive decline. Objective: To evaluate the effect of tau synthesis reduction on tau biomarkers in patients with mild AD. Design, Setting, and Participants: This randomized clinical trial was a double-blind, placebo-controlled 36-week multiple-ascending dose (MAD) phase 1b trial (October 2017 to September 2020), followed by a 64- or 71-week open-label long-term extension (LTE) (October 2019 to May 2022). After being assessed for eligibility at 12 sites in Canada and Europe, participants with mild AD and confirmed amyloid pathology were randomized 3:1 (BIIB080:placebo) in 4 dose cohorts. Intervention: Intrathecal administration of BIIB080, a MAPT-targeting antisense oligonucleotide, or placebo. Active dose arms included 10 mg every 4 weeks, 30 mg every 4 weeks, 60 mg every 4 weeks, and 115 mg every 12 weeks during the MAD period and 60 mg every 12 weeks or 115 mg every 12 weeks during the LTE. Main Outcome and Measures: The original primary end point was safety. Additionally, BIIB080, total tau (t-tau), and phosphorylated tau 181 (p-tau181) cerebrospinal fluid (CSF) concentrations were evaluated. Tau positron emission tomography (PET) was collected in a substudy, and standard uptake value ratios (SUVRs) were calculated in a priori-defined composite regions of interest. Results: Of 102 participants assessed for eligibility, 46 participants with mild AD were enrolled; 23 (50%) were female, and mean (SD) age was 65.8 (5.70) years. BIIB080 was generally well tolerated and was associated with a dose-dependent reduction in CSF t-tau and p-tau181 in the MAD period (56% reduction; 95% CI, 50% to 62%; and 51% reduction; 95% CI, 38% to 63%, of CSF t-tau in the 2 higher-dose cohorts) that continued and/or was maintained through quarterly dosing in the LTE. Tau PET demonstrated reduced accumulation vs placebo at week 25 (n = 13). At week 100, tau PET showed a reduction from baseline across all regions assessed (n = 12), with the largest reductions from baseline observed in the temporal composite (-0.71 SUVR; 95% CI, -1.40 to -0.02). A moderate correlation was observed between model-predicted cumulative CSF drug exposure and tau PET change. Conclusions and Relevance: In this randomized clinical trial, BIIB080 reduced tau biomarkers, including CSF t-tau, CSF p-tau181, and tau PET, which is associated with cognitive decline, in participants with mild AD. Effects of BIIB080 on biomarkers and clinical outcomes are being further evaluated in a phase 2 trial. Trial Registration: ClinicalTrials.gov Identifier: NCT03186989.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu